← Eichor
Study identifier: NCT06954597 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis

Condition: Digital Ulcers in Systemic Sclerosis  ·  Sponsor: Topadur Pharma AG

PhasePhase 2
Planned participants15
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The main goal of this clinical trial is to learn about how safe the new drug TOP-N53 solution is when it is applied to open wounds on the fingertip (digital ulcers) in people with an uncommon illness that results in hard, thickened areas of skin and additional problems with internal organs and blood vessels (systemic sclerosis). Another goal is to learn if different strengths of TOP-N53 can treat certain aspects of the illness. Men and women between 18 and 69 years of age with this illness may participate in the clinical trial. A parallel treatment with Sildenafil 20 mg is allowed for clinical trial participants. The main questions the clinical trial aims to answer are: * Does TOP-N53 cause medical problems at the fingertip wound after it is directly applied to the wound? * Does TOP-N53 affect certain aspects of the illness like blood flow in the fingertip wounds, itch, pain, redness, bruises and bleeding at or beyond the fingertip wounds? Researchers will compare TOP-N53 solution in different strengths to a placebo (a look-alike substance that contains no drug) to see if TOP-N53 works to affect the aspects of the illness listed above. Participants will receive one or two treatments with the placebo or different strengths of TOP-N53. The higher strength of the drug will only be given to participants after the lower strength was found to be safe. Participants will visit the clinic up to 8 times within a maximum of 31 days. 2 visits may be done by telephone. The doctors wi…

This description comes directly from the study's public registry record.

Talk to the study team

Claudia Berger, Ph.D.  ·  +41792025755  ·  claudia.berger@Topadur.com

Always discuss trial participation with your own doctor first.

Locations (6)

Centre Hospitalier Universitaire de Bordeaux, Service de RhumatologieBordeaux, FranceRecruiting
CHU Grenoble AlpesLa Tronche, FranceRecruiting
CHRU Lille, Hôpital Claude Huriez, Rue Michel PolonosvskiLille, FranceRecruiting
AP-HP Hôpital CochinParis, FranceRecruiting
Reha Rheinfelden, Salinenstrasse 98Rheinfelden, Canton of Aargau, SwitzerlandRecruiting
Universitätsspital Zürich, Klinik für Rheumatologie, Rämistrasse 100Zurich, Canton of Zurich, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06954597